<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106067">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02130362</url>
  </required_header>
  <id_info>
    <org_study_id>P11-292</org_study_id>
    <nct_id>NCT02130362</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)</brief_title>
  <acronym>CAPE</acronym>
  <official_title>A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Portugal: Health Ethic Committee</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Bulgaria: Ethics committee</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>Bosnia: Federal Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>France: Conseil National de l'Ordre des MÃ©decins</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Estonia: Research Ethics Committee</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>Greece: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in
      pediatric patients with moderately to severely active CD who are treated as recommended in
      the product label.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of subjects with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with SAEs</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with AESI of infections, malignancies, and pregnancies</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with other AESI</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects with AESIs other than infections and malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with other AESI</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentages of subjects with AESIs other than infections and malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent SAEs per 100 patient years (PYs)</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent AESI per 100 PYs of infections and malignancies</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent other AESI per 100 PYs</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Pediatric Crohn's Disease Activity Index (sh-PCDAI)</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient completed questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Disease Activity (PGA)</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Completed by the physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPACT III</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Completed by patients ages 10 through 17 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Completed by the patients who are 18 years of age or older</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI) questionnaire</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Completed by caregiver up to the age of 17 years and completed by the patients of age 18 years or above.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Adalimumab (Humira) Treatment</arm_group_label>
    <description>Pediatric patients who are prescribed and treated with adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunosuppressant Therapy</arm_group_label>
    <description>Pediatric patients who are being prescribed and treated with immunosuppressant therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients with moderately to severly active Crohn's Disease (CD) who have
        prescribed HUMIRA according to the local label and pediatric patients being prescribed and
        treated with IMM (azathioprine, 6-mercaptopurine, or methotrexate). Patients being
        prescribed and treated with immunosuppressant therapy with no concurrent biologic use will
        be enrolled as a reference group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For a patient enrolling into the HUMIRA treatment group; A pediatric patient between
             the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with
             moderately to severely active CD who has been prescribed Humira therapy according to
             the local approved Humira product label.

          2. For a patient enrolling into the immunosuppressant therapy treatment group; A
             pediatric patient between the ages of 6 and 17 years inclusive at the time of
             enrollment, diagnosed with moderately to severely active CD who has been prescribed
             azathioprine, 6-mercaptopurine or methotrexate.

          3. Parent or guardian; or patient (if 18 years of age or older at enrollment and rolling
             over from an AbbVie-sponsored investigational Pediatric CD investigation trial) has
             voluntarily signed and dated an Authorization for Use/Disclosure of Data
             (AUDD)/informed consent form (ICF) after the nature of the registry has been
             explained and the patient, patient's parent or legal guardian has had the opportunity
             to ask questions.

        Exclusion Criteria:

          1. Patients should not be enrolled into the HUMIRA treatment group if they cannot be
             treated in accordance with the local Humira product label.

          2. Patients should not be enrolled into the registry if they are currently being treated
             with any investigational agents or are receiving any investigational procedures.

          3. Patients should not be enrolled into the immunosuppressant therapy treatment group if
             they require ongoing treatment with approved biologic agents including HUMIRA.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas  Lazar, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie  Gavigan, BS</last_name>
    <phone>8479375472</phone>
    <email>julie.gavigan@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura  Swingle, BS</last_name>
    <phone>8474149409</phone>
    <email>laura.swingle@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127435</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127435</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127912</name>
      <address>
        <city>Halifax</city>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127912</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127911</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127911</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127910</name>
      <address>
        <city>Toronto</city>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127910</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127437</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127437</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127913</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127913</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126122</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126122</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127697</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127697</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126974</name>
      <address>
        <city>Tallinn</city>
        <zip>Ravi 27</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126974</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126591</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126591</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127696</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127696</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127975</name>
      <address>
        <city>Forchheim</city>
        <zip>91301</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127975</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126035</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126035</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127438</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127438</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127436</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127436</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126972</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 126972</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Registry</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Adalimumab</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
